Sprint Bioscience AB Total Liabilities
Sprint Bioscience AB total liabilities. Based on the latest financial reports, Sprint Bioscience AB (SPRINT) has total liabilities worth Skr12.69 Million SEK (≈ $1.37 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Sprint Bioscience AB asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Sprint Bioscience AB (2011–2025)
Total liabilities of Sprint Bioscience AB from 2011 to 2025. This chart illustrates how Sprint Bioscience AB's total liabilities have evolved over time, based on quarterly financial data.
Sprint Bioscience AB Competitors by Total Liabilities
The table below lists competitors of Sprint Bioscience AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Anson Resources Ltd
AU:ASN
|
Australia | AU$3.98 Million |
|
Hyundai HT CoLtd
KQ:039010
|
Korea | ₩31.05 Billion |
|
Dividend Select 15 Corp
TO:DS
|
Canada | CA$503.98K |
|
Taiwan Benefit Co
TWO:3379
|
Taiwan | NT$572.57 Million |
|
MClean Technologies Bhd
KLSE:0167
|
Malaysia | RM33.10 Million |
|
Eightco Holdings Inc.
NASDAQ:OCTO
|
USA | $40.18 Million |
|
H2APEX Group SCA
XETRA:H2A
|
Germany | €77.00 Million |
|
ACELRX PHARMACEUT. DL-01
F:R5XA
|
Germany | €12.68 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Sprint Bioscience AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Sprint Bioscience AB.
Liquidity & Leverage Metrics
Sprint Bioscience AB Total Liabilities Ratios Explained
Sprint Bioscience AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sprint Bioscience AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sprint Bioscience AB (2011–2025)
The table below shows the annual total liabilities of Sprint Bioscience AB from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr17.48 Million ≈ $1.88 Million |
-46.67% |
| 2024-12-31 | Skr32.78 Million ≈ $3.53 Million |
-5.26% |
| 2023-12-31 | Skr34.60 Million ≈ $3.72 Million |
+274.73% |
| 2022-12-31 | Skr9.23 Million ≈ $993.73K |
+6.35% |
| 2021-12-31 | Skr8.68 Million ≈ $934.43K |
-64.20% |
| 2020-12-31 | Skr24.25 Million ≈ $2.61 Million |
+194.82% |
| 2019-12-31 | Skr8.23 Million ≈ $885.36K |
-62.68% |
| 2018-12-31 | Skr22.05 Million ≈ $2.37 Million |
+198.09% |
| 2017-12-31 | Skr7.40 Million ≈ $795.93K |
-64.83% |
| 2016-12-31 | Skr21.03 Million ≈ $2.26 Million |
-18.54% |
| 2015-12-31 | Skr25.81 Million ≈ $2.78 Million |
+434.79% |
| 2014-12-31 | Skr4.83 Million ≈ $519.44K |
+17.47% |
| 2013-12-31 | Skr4.11 Million ≈ $442.19K |
+28.24% |
| 2012-12-31 | Skr3.20 Million ≈ $344.81K |
+329.45% |
| 2011-12-31 | Skr746.09K ≈ $80.29K |
-- |
About Sprint Bioscience AB
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of drug candidates to treat cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; DCPS which is in preclinical trial for the treatment of acute myeloid leukemia; VRK1, which is in preclinical development to treat solid tumors; VPS34, a d… Read more